{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-211922","form_type":"8-K","ticker":"ASMB","cik":"0001426800","company_name":"ASSEMBLY BIOSCIENCES, INC.","filed_at":"2026-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.270859+00:00","generated_at":"2026-05-14T21:33:45.830846+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Q1 net loss $9.1M ($0.54/sh); cash $226.6M; HPI opt-in decision pending mid-2026","bullets":["Net loss $9.1M ($0.54/share) vs $8.8M ($1.17/share) in Q1 2025; cash $226.6M at quarter end.","Gilead collaboration revenue $8.2M, down from $9.4M YoY; R&D expenses flat at $14.9M.","Completed Phase 1b for ABI-5366/1179 (genital herpes); to decide on 40% U.S. cost-profit share opt-in by mid-2026.","Completed chronic tox for ABI-6250 (HDV entry inhibitor); Phase 2 start expected Q4 2026.","Cash runway projected into 2028."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-211922","json":"https://secwatch.observer/filing/0001193125-26-211922.json","markdown":"https://secwatch.observer/filing/0001193125-26-211922.md","text":"https://secwatch.observer/filing/0001193125-26-211922.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1426800/000119312526211922/0001193125-26-211922-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1426800/000119312526211922/asmb-20260507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T21:33:45.830846+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"75d906921499c2609d3b647c4654a427361cf5a4","claim":"ASSEMBLY BIOSCIENCES, INC. reported the quarter ended March 31, 2026 results: revenue $8.2 million, net income Net loss attributable to common stockholders was $9.1 million, or $0.54 per basic and diluted share, EPS $0.54 per basic and diluted share.","evidence_excerpt":"compared to $248.1 million as of December 31, 2025. The company’s cash position is projected to fund operations into 2028. • Revenue from collaborative research with Gilead was $8.2 million for the three months ended March 31, 2026, compared to $9.4 million for the same period in 2025. The decrease reflects the timing of activities performed and progress toward","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1426800/000119312526211922/0001193125-26-211922-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2026"},{"label":"Revenue","value":"$8.2 million"},{"label":"Net income","value":"Net loss attributable to common stockholders was $9.1 million, or $0.54 per basic and diluted share"},{"label":"EPS","value":"$0.54 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}